Summit Therapeutics Inc. income statement

In fiscal 2024, Summit Therapeutics Inc. reported revenue of $0 and net income of −$221m, or −$0.31 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Summit Therapeutics Inc.: income statement, annual
Fiscal year	2016Jan 2016	2017Jan 2017	2018Jan 2018	2019Jan 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024
Revenue	0	3	33	57	1	2	1	0	0
Gross profit	−31	−33	−34	—	—	—	—	—	—
Research and development	—	—	—	52	53	85	52	59	151
General and administrative	—	—	—	17	19	24	27	29	60
Operating income	—	—	—	5	−53	−86	−72	−610	−226
Interest expense	—	—	—	1	0	0	4	16	9
Income before tax	—	—	—	9	−53	−89	−79	−615	−221
Income tax	—	—	—	−2	−0	0	—	0	0
Net income	−31	−29	−26	11	−53	−89	−79	−615	−221
Diluted EPS	—	−$0.06	−$0.05	$0.06	−$0.27	−$0.48	−$0.41	−$0.99	−$0.31
Diluted shares (average)	473m	492m	523m	194m	196m	185m	193m	620m	719m
EBITDA	—	—	—	6	−53	−86	−72	−609	−226

US$ millions unless shown otherwise. Fiscal quarters.

Summit Therapeutics Inc.: income statement, quarterly
Quarter	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q3Sept 2024	2024 Q4Dec 2024
Revenue	0	0	0	0	0	0	0	0
Research and development	17	5	10	9	15	25	38	51
General and administrative	6	8	7	6	5	11	21	14
Operating income	−17	−20	−537	−16	−20	−36	−58	−66
Interest expense	1	3	8	3	3	3	2	0
Net income	−21	−19	−542	−15	−21	−37	−56	−61
Diluted EPS	−$0.10	−$0.04	−$1.43	−$0.02	−$0.03	−$0.01	−$0.08	−$0.09
EBITDA	−17	−20	−537	−16	−20	−36	−58	−66

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Summit Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Summit Therapeutics Inc.